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Abstract Plasminogen activator inhibitor-I (PAl-l), an impor- 
tant risk factor for thrombotic diseases, is a member of the 
superfamily of serine proteinase inhibitors. To define structural 
rearrangements occurring during interaction between PAI-I and 
its target proteinases we have raised monoclonal antibodies 
against the PAI-IIt-PA complex. Thirteen out of 401 monoclonal 
antibodies reacted preferentially with the PAI-IIt-PA complex as 
compared to free PAI-I or free t-PA. Detailed characterization 
revealed the presence of two non-overlapping neoantigenic epi- 
topes in the PAI-IIt-PA complex. Both neoantigenic epitopes 
were also exposed after complex formation between PAI-I and 
either urokinase-type plasminogen activator, plasmin or thrombin 
as well as after cleavage of the reactive site loop of non-inhibitory 
substrate type PAI-I variants. Thus, we have identified two 
neoantigenic epitopes, localized entirely in PAl-l ,  and commonly 
exposed after complex formation of active PAI-I with various 
proteinases or after cleavage of substrate PAI-I. These monoclo- 
nal antibodies hould facilitate further studies on the mechanism 
of interaction between various PAI-I forms and its target pro- 
teinases. 
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1. Introduction 
Plasminogen activator inhibitor-1 (PAI-1) is the main physi- 
ological inhibitor of tissue-type plasminogen activator (t-PA) 
in plasma [1]. Elevated levels of PAI-1 in plasma re associated 
with an increased risk ofthromboembolism uggesting a critical 
role of PAI-I in the in vivo regulation of fibrinolysis [2]. PAI-1 
is a single-chain glycoprotein and is a member of the serine 
proteinase inhibitor (serpin) family [3-6]. PAI-1 inhibits both 
tissue-type plasminogen activator (t-PA) and urokinase-type 
plasminogen activator (u-PA) with second-order rate constants 
of 107 M -~'s -~ [7]. In addition, complex formation of PAI-I 
with plasmin and thrombin has also been reported [8]. PAI-I 
exhibits a unique conformational flexibility. It is synthesised as 
an active form that spontaneously converts to a latent form that 
can be partially reactivated by denaturing agents such as so- 
dium docecyl sulfate, guanidinium chloride and urea [9]. Re- 
cently, a third conformation reacting as a non-inhibitory sub- 
strate has been identified [10]. 
The reactive site loop of serpins comprises 20 to 30 amino 
acids (P17 to P~0') at the carboxy terminal side of the protein. 
The bait peptide bond (Pt P~') in PAI-I corresponds to the 
Arg346-Met347 bond [11]. Active serpins inhibit their target pro- 
teinases by formation of a 1 : 1 stoichiometric reversible com- 
plex followed by a covalent binding between the hydroxylgroup 
of the active-site serine residue of the proteinase and the car- 
boxylgroup of the Pt residue at the reactive center of the serpin 
[12]. Thus interaction between active PAI-1 and its target pro- 
teinases results in the formation of a stable covalent complex. 
Recent crystallographic data [13] have suggested that in latent 
PAI-1, the bait region and secondary binding sites are not 
accessible for interaction with its target proteinases. In con- 
trast, the inactive substrate form reacts with its target pro- 
teinase resulting in a cleavage of the P1-P~' bond without for- 
mation of a stable complex [10,14]. Molecular details of the 
conformational differences responsible for the functional diver- 
sity of PAI-1 are not yet identified. 
In the current study, a large panel of monoclonal antibodies 
was generated against he PAI-1/t-PA complex. Two neoanti- 
genic epitopes could be identified in the PAI-1/t-PA complex 
that were also exposed in PAI-1 complexed with other pro- 
teinases as well as in cleaved PAI-1 generated from substrate 
PAI-1. 
2. Materials and methods 
2.1. Materials 
96-well polystyreen microtiterplates were purchased from Costar 
(Cambridge, MA), RAM-IgG-HRP was from Nordic (Tilburg, The 
Netherlands). Dulbecco's modified Eagle's medium was from ICN 
Pharmaceuticals Inc. (Costa Mesa, CA). t-PA was a kind gift from 
Boehringer Ingelheim (Brussels, Belgium). Urokinase-type lasmino- 
gen activator (u-PA) was kindly provided by Bournonville Pharma 
(Braine-l'Alleud, Belgium). Plasmin and thrombin were kind gifts from 
Dr. R. Lijnen (University of Leuven, Belgium). All other chemicals and 
reagents were of the highest quality available. 
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2.2. Preparation of recomb&ant proteins and of the purified plasminogen 
activator inhibitor-l/tissue-type lasminogen activator complex 
Recombinant wt-PAI-1 and PAI-I mutants were expressed inE. coli 
and purified as described previously [14]. PAI-1 activity was measured 
by the method escribed by Verheijen et al. [15] or by an immunofunc- 
tional method [16]. t-PA was calibrated versus the international refer- 
ence preparation for t-PA (NIBSC 86/670; obtained from the National 
Institute for Biological Standards and Controls, London, UK). PAI-I 
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antigen was determined by ELISA [17] or spectrophotometrically t 
280 nm using an absorbance coefficient A~)  of 10. 
The PAI-1/t-PA complex used for immunization and selection of 
hybridomas was obtained as follows. Purified PAI-1 (~500000 U) was 
incubated with t-PA (~400000 U) for 25 min at 37°C. This mixture was 
then applied on a Sepharose 4B column to which a monoclonal anti- 
body against -PA (MA-62E8) was coupled. Bound antigen (i.e. PA1- 
I/t-PA complex) was eluted with 3 M KSCN. PAI-1/t-PA containing 
fractions were pooled and dialyzed against Tris 50 mM/Arginine 250 
mM, pH 8.3. Concentration ofPAI-I/t-PA complex was determined as 
described previously [16]. The purity of the preparations was assessed 
by SDS-PAGE using 10-15% gradient gels under non-reducing condi- 
tions with the Pharmacia Phast System (Upsala, Sweden). Proteins were 
visualized by staining with Coomassie brilliant blue. 
2.3. Preparation of enzl,me-PAl-1 complexes' and of enzyme-cleaved 
PAl,1 
Complexes of PAI-1 with t-PA and u-PA were prepared by incuba- 
tion (25 rain at 37°C) of purified PAI-1 with a 2-fold molar excess of 
t-PA or u-PA, respectively. PAI-1/plasmin and PAI-1/thrombin com- 
plexes were prepared by incubation of PAI-I for 2 h at 37°C with a 
2-fold molar excess of plasmin and thrombin, respectively. 
Cleaved PA]-I (at PI-P~') was prepared by incubation of the non- 
inhibitory PAI-I mutants, PAI-1 A335P (alanine at position Pl2 substi- 
tuted by a proline) and PAI-l-T333P (threonine at position P~4 substi- 
tuted by a proline), both exhibiting substrate characteristics [14,18], 
with a 2-fold molar excess of t-PA or u-PA for 25 min at 37°C. 
Formation of complexes and cleavage products was verified by SDS- 
PAGE followed by staining with Coomassie brilliant blue. 
2.4. Preparation of monoclonal ntibodies against PAI-1/t-PA 
Monoclonal antibodies against the purified PAI-1/t-PA complex 
were produced by the method of Galfr~ and Milstein [19]. PA[-1 -/- 
deficient mice [20] were immunized by subcutaneous injection of 10 ,ug 
PAI-I/t-PA complex in complete Freund's adjuvant, which was fol- 
lowed 2 weeks later by intraperitoneal injection of 10 pg PAI-1/t-PA 
complex in incomplete Freund's adjuvant. After an interval of at least 
6 weeks, the mice were boosted intraperitoneally with 10,ug PAI-1/t-PA 
in saline on days 4 and 2 before the cell fusion. Spleen cells were isolated 
and fused with Sp2/0-Agl4 myeloma cells according to Fazekas de St 
Groth and Scheidegger [21]. After selection in hypoxanthine, amino- 
pterine, thymidine medium, culture supernatants were screened for 
specific antibody production by ELISA, using microtiterplates coated 
with PAI-1/t-PA. The bound immunoglobulins were detected with 
horseradish peroxidase(HRP)-conjugated rabbit antimouse IgG 
(RAM-HRP). Supernatants yielding a positive response were subjected 
to a second screening (4-fold dilutions ranging from 1 : 10 to 1 : 10240) 
using microtiterplates coated with either PAI-1 or t-PA. Positive clones 
were used for the production ofascitic fluid in pristane-primed BALB/c 
mice [22]. The IgG fraction of the monoclonal antibodies was purified 
from ascites by affinity chromatography on protein A°sepharose [23]. 
HRP-conjugated monoclonal ntibodies were produced as described by 
Nakane and Kawaoi [24]. 
2.5. Determination f overlapping epitopes 
The occurrence of overlapping epitopes in a selected panel of mono- 
clonal antibodies (n = 13, see Discussion) was evaluated as follows. 
Microtiterplates were coated with the monoclonal antibodies and sub- 
sequently blocked with bovine serum albumin [17]. Samples (containing 
PAI-1/t-PA) were diluted in PBS containing Tween 80 (0.002%), EDTA 
(5 mM) and bovine serum albumin (1 g/l) (dilution buffer), and added 
to the wells. After incubation for 18 h at 4°C in a moist chamber, the 
wells were emptied and washed with PBS/Tween. Subsequently, the 
capacity to bind simultaneously another monoclonal antibody was 
evaluated by incubation (2 h at room temperature) of the wells with 
various HRP-conjugated monoclonal ntibodies (1:4000). After wash- 
ing the plates, 160 pl aliquots of a 0.1 M citrate, 0.2 M sodium phos- 
phate buffer, pH 5.0, containing 300 pg/ml o-phenylenediamine and 
0.003% hydrogen peroxide were added. After 30 to 60 min at room 
temperature the peroxidase reaction was stopped with 50/11 of 4 M 
H2SO4. The absorbance was measured at 492 nm with a multiscan 
spectrophotometer (Spectra III/SLT, Salzburg, Austria). Binding of a 
conjugated antibody, as evidenced by a positive response in the above- 
mentioned procedure, indicates that the coated and the conjugated 
antibody recognize a different epitope, Lack of binding indicates that 
both antibodies are directed against he same epitope or that a signifi- 
cant portion of the epitopes overlap. Each antibody was evaluated as 
coating antibody in combination with all antibodies conjugated to HRP 
(n= 13x13). 
2.6. Detection of neoantigenic epitopes invarious other PAl,1 derivatives 
The occurrence of common neoantigenic epitopes in PAI-1 deriva- 
tives other than the purified PAI-I/t-PA complex initially used for 
generation and screening of the antibodies was studied as follows. Two 
antibodies, i.e. MA-13CI and MA-14D5-HRP, each representing a 
different neoantigenic epitope (see Results) in PAI-1/t-PA, were used 
to construct an ELISA as described above. Subsequently, the different 
PAI-l-related preparations were analyzed in various concentrations 
ranging from 500 ng/ml to 0.3 ng/ml and using serial 2-fold dilutions. 
Comparison of the reactivity of the PAI-I derivatives studied in this 
ELISA then revealed either the presence or the absence of neoantigenic 
epitopes exposed in the various PAl-1 derivatives. 
3. Results and discussion 
3.1. Generation of monoclonal ntibodies against the 
PAI-1lt-PA complex and detection of neoantigenic epitopes 
Out of two fusions, 401 positive hybridomas were obtained 
producing a monoclonal  ant ibody reactive with the PAI-1/t-PA 
complex. 285 and 103 clones reacted equally well with the 
PAI- l /t -PA complex and with t-PA or PAI-1, respectively, 
whereas 13 reacted strongly with the PAI-I /t-PA complex, not 
with free t-PA and only weakly with free PAI-1. Fig. 1 shows 
the dose-response curves for two monoclonal antibodies (e.g. 
MA-13C1 and MA-14D5) exhibiting a strong reactivity to- 
wards the complex, whereas their reactivity with free PAI-1 is 
50 to 250-fold lower and no reactivity with free t-PA could be 
observed. These 13 monoclonal  antibodies directed against a 
neoantigenic epitope were purified from ascites and were fur- 
ther subjected to a detailed epitope mapping as described in the 
methods. The data clearly revealed the presence of at least two 
non-overlapping, neoantigenic epitopes. 
The results demonstrate that in the PAI-1/t-PA complex epi- 
topes are present which were not previously occurring in the 
free reactants. These neoepitopes may have arisen in the PAI- 
1/t-PA complex consequent to (a) a combinat ion (either three- 
dimensional or linear) of amino acid residues originating from 
PAI-1 and t-PA or (b) a rearrangement in either PAI-1 or t-PA 
resulting in the exposure of regions previously undetectable in
either one of the free moieties. However, the monoclonal  anti- 
bodies currently selected id not react with t-PA but did react 
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Fig. 1. Reactivity of culture supernatants (dilutions ranging from 1 : l0 
to 1:10240) of MA-13C1 (1, [], v) and MA-14D5 (e, o, ~) towards 
various PAI-1 derivatives: PAI-1/t-PA (m, e); free PAI-1 ([], o) and free 
t-PA (,7, A). 
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Fig. 2. Exposure of neoantigenic epitopes in PAl-1 complexed to vari- 
ous serine proteinases. Dose-response curves in the MA-13CI/MA- 
14D5-HRP ELISA are shown for free PAI-1 (0) and (A) PAI-1 com- 
plexed with t-PA (A) or u-PA (v); and (B) PAI-I complexed with 
plasmin (&) or thrombin (v). 
weakly with free PAI-1. The latter observation is suggestive for 
a specific rearrangement that would have occurred in PAI-1. 
3.2. Detection o]common eoantigenic epitopes in various PAL1 
derivatives 
Two monoclonal antibodies (i.e. MA-13C1 and MA-14D5) 
each representing a distinct neoantigenic epitope, were used as 
capture and tagging antibody, respectively, to evaluate whether 
these neoantigenic epitopes might occur in various other PAI-I 
derivatives. 
Fig. 2 shows typical dose-response curves for free PAI-1 and 
for PAI-1/t-PA, PAI-1/u-PA, PAI-1/plasmin and PAI-1/throm- 
bin complexes in the MA-13CI/MA-14D5-HRP ELISA. From 
these data it appears that all complexed forms of PAI-1 exhibit 
an increased reactivity compared to free PAI-1 (> 160- to >200- 
fold). The similarly enhanced reactivity towards complexed 
PAI-1 irrespective of the serine proteinase used substantiates 
the hypothesis that the neoantigenic epitopes are located en- 
tirely in the PAI-l-moiety of the complex, originating from the 
interaction between PAI-1 and its target proteinases, i.e. t-PA, 
u-PA, plasmin or thrombin. 
Dose-response curves before and after incubation (with t-PA 
or u-PA) of the inactive variants PAI-1-A335P and PAI-1- 
T333R both exerting a substrate behaviour [14,18], revealed 
that these neoantigenic epitopes are also generated after cleav- 
age (at the P~-P~' bond) of the inactive substrate PAI-1 form. 
PAI-1-T333P cleaved with t-PA was 102 + 23 (n = 7) times 
more reactive compared to intact PAI-I T333P: cleavage with 
u-PA resulted in an increased reactivity of 184 + 48 (n = 7) fold. 
PAI-1-A335P cleaved with t-PA or u-PA was 43 -+ 17 (n = 9) 
and 101 + 54 (n = 8), respectively, more reactive as compared 
to intact PAI-1-A335P. 
These findings confirm that the monoclonal antibodies repre- 
sent two newly exposed epitopes that are exclusively located in 
the PAI-1 moiety of the reaction product formed between PAI- 
l, either eacting as an inhibitor or as a substrate, and the serine 
proteinases. It is important to note that a weak but significant 
reactivity is also observed for the intact substrate PAI-1 vari- 
ants, indicating that the epitopes, covered by these 2 monoclo- 
nal antibodies, are partially expressed in the intact PAI-1 mu- 
tants. Most likely the distortion of the reactive site loop induced 
by the introduction of a proline results in a partial exposure of 
these epitopes. 
Similar studies have been performed with the serpins an- 
tithrombin III [25-27] and Cl-inhibitor [28 30]. Asakura et al. 
reported the preparation and characterization f five monoclo- 
hal antibodies against neoantigenic epitopes in the thrombin/ 
antithrombin III complex out of 18 antibodies directed against 
the complex. One out of these five monoclonal antibodies was 
found to interfere with the inhibition of thrombin by antithrom- 
bin III. However, in our current study, none of the monoclonal 
antibodies against the neoantigenic epitopes did affect he func- 
tional behaviour of PAI-1 i.e. more than 80% of the PAI-1 
activity was recovered after incubation of PAl-1 with a ten-fold 
molar excess of monoclonal antibody. This indicates that the 
epitopes recognized by the antibodies are not located in the 
near vicinity of the active site residues Arg346-Met347 of PAI-I. 
de Agostini et al. [28,29] nor Nuijens et al. [30] provided infor- 
mation on the functional effects of their monoclonal antibodies. 
From our current data it is clear that the two distinct neoanti- 
genic epitopes are entirely located in PAI-1 and become acces- 
sible only after conformational changes pecifically induced by 
interaction with its target proteinases. None of the 13 monoclo- 
nal antibodies can detect he PAI-1/t-PA complex or cleaved 
PAI-I in Western blots (data not shown) strongly suggesting 
that the neoantigenic epitopes are discontinuous epitopes [31] 
generated by the assembly of residues that were not adjacent 
in free intact PA]-I. 
It is well-known that covalent complex conformation be- 
tween serpins and their target proteinases i  associated with a 
cleavage of the bait peptide bond P] Pt' [32-34]. Therefore, in 
view of the observation that both neoantigenic epitopes are 
exposed in complexed as well as in cleaved PAl-l, it is most 
likely that cleavage of the P1-PI' bond is a major event respon- 
sible for the generation of these epitopes. Recent structural 
studies on PAI-I have shown that in cleaved PAI-1 [35] the 
aminoterminal portion of the reactive site loop (i.e. PI6--PL) 
forms a new fl-strand in s4A by insertion into fl-sheet A. This 
particular feature is similar to that observed in latent PAI-1 
[13]. Since the antibodies react with cleaved but not with latent 
PAI-1 it can be concluded that rearrangement of P~6 P~ in 
PAI-I does not play an important role, if any, for the genera- 
tion of the neoepitopes. This is in contrast o the observation 
of Asakura et al. [27] identifying a neoantigenic epitope, in the 
thrombin/antithrombin II! complex, mainly composed of the 
P~2-P8 region located at the NH2-terminal part of the cleavage 
site of antithrombin III. However, one of the major differences 
between cleaved PAI-1 and intact latent PAI-1 is the formation 
of a new fl-strand slC involving P~' to Pt3' of the reactive site 
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loop [35] indicating that this region might contribute signifi- 
cantly to the differential reactivity of our antibodies. This hy- 
pothesis is also compatible with the observation that these 
antibodies do not interfere with PAI-1 activity whereas those 
reported by Asakura et al. [26,27] do neutralize antithrombin 
III activity. 
In conclusion, we succeeded to raise and identify monoclonal 
antibodies against two distinct neoantigenic epitopes in the 
PAI-1/t-PA complex. These epitopes were found to be localized 
entirely in the PAI-I moiety and evidence was obtained that the 
conformational rearrangements in the C-terminal portion of 
the reactive site loop contribute significantly to their exposure. 
Such antibodies have not been described for PAI-I yet and 
comparison with data for other serpins shows that the current 
neoantigenic epitopes are most likely located in different re- 
gions than those reported for other serpins. 
These monoclonal antibodies may constitute useful tools for 
further studies on the conformational nd functional f exibility 
of PAI- 1 and on the mechanism of interaction between various 
PAI-I forms and its target proteinases. 
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